These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 8855792)

  • 1. Immunocytochemical detection of p53 in human thyroid carcinomas is associated with mutation and immortalization of cell lines.
    Jossart GH; Epstein HD; Shaver JK; Weier HU; Greulich KM; Tezelman S; Grossman RF; Siperstein AE; Duh QY; Clark OH
    J Clin Endocrinol Metab; 1996 Oct; 81(10):3498-504. PubMed ID: 8855792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas.
    Fagin JA; Matsuo K; Karmakar A; Chen DL; Tang SH; Koeffler HP
    J Clin Invest; 1993 Jan; 91(1):179-84. PubMed ID: 8423216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 mutations in all stages of thyroid carcinomas.
    Zou M; Shi Y; Farid NR
    J Clin Endocrinol Metab; 1993 Oct; 77(4):1054-8. PubMed ID: 8408453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutation of the p53 gene in a differentiated human thyroid carcinoma cell line, but not in primary thyroid tumours.
    Wright PA; Lemoine NR; Goretzki PE; Wyllie FS; Bond J; Hughes C; Röher HD; Williams ED; Wynford-Thomas D
    Oncogene; 1991 Sep; 6(9):1693-7. PubMed ID: 1923534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas.
    Elisei R; Shiohara M; Koeffler HP; Fagin JA
    Cancer; 1998 Nov; 83(10):2185-93. PubMed ID: 9827724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bax expression in benign and malignant thyroid tumours: dysregulation of wild-type P53 is associated with a high Bax and P21 expression in thyroid carcinoma.
    Hermann S; Sturm I; Mrozek A; Klosterhalfen B; Hauptmann S; Dörken B; Daniel PT
    Int J Cancer; 2001 Jun; 92(6):805-11. PubMed ID: 11351299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contribution of p53 gene alterations to development of metastatic forms of follicular thyroid carcinoma.
    Sápi Z; Lukács G; Sztán M; Papp J; Oláh E
    Diagn Mol Pathol; 1995 Dec; 4(4):256-60. PubMed ID: 8634781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FHIT and TSG101 in thyroid tumours: aberrant transcripts reflect rare abnormal RNA processing events of uncertain pathogenetic or clinical significance.
    McIver B; Grebe SK; Wang L; Hay ID; Yokomizo A; Liu W; Goellner JR; Grant CS; Smith DI; Eberhardt NL
    Clin Endocrinol (Oxf); 2000 Jun; 52(6):749-57. PubMed ID: 10848880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
    Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic mutations in thyroid carcinoma.
    Taccaliti A; Boscaro M
    Minerva Endocrinol; 2009 Mar; 34(1):11-28. PubMed ID: 19209125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alterations of p53 and expression of WAF1/p21 in human thyroid tumors.
    Zedenius J; Larsson C; Wallin G; Bäckdahl M; Aspenblad U; Höög A; Børresen AL; Auer G
    Thyroid; 1996 Feb; 6(1):1-9. PubMed ID: 8777377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of mutations of ras and p53 in benign and malignant thyroid tumors from children exposed to radiation after the Chernobyl nuclear accident.
    Nikiforov YE; Nikiforova MN; Gnepp DR; Fagin JA
    Oncogene; 1996 Aug; 13(4):687-93. PubMed ID: 8761289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The natural protein kinase C alpha mutant is present in human thyroid neoplasms.
    Prévostel C; Alvaro V; de Boisvilliers F; Martin A; Jaffiol C; Joubert D
    Oncogene; 1995 Aug; 11(4):669-74. PubMed ID: 7651730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations of the p53 gene in human functional adrenal neoplasms.
    Lin SR; Lee YJ; Tsai JH
    J Clin Endocrinol Metab; 1994 Feb; 78(2):483-91. PubMed ID: 8106638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of p16/CDKN2 alterations in thyroid carcinomas.
    Yane K; Konishi N; Kitahori Y; Naito H; Okaichi K; Ohnishi T; Miyahara H; Matsunaga T; Hiasa Y
    Cancer Lett; 1996 Mar; 101(1):85-92. PubMed ID: 8625287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland.
    Ito T; Seyama T; Mizuno T; Tsuyama N; Hayashi T; Hayashi Y; Dohi K; Nakamura N; Akiyama M
    Cancer Res; 1992 Mar; 52(5):1369-71. PubMed ID: 1737400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is atypical follicular adenoma of the thyroid a preinvasive malignancy?
    Tzen CY; Huang YW; Fu YS
    Hum Pathol; 2003 Jul; 34(7):666-9. PubMed ID: 12874762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
    Xu X; Quiros RM; Gattuso P; Ain KB; Prinz RA
    Cancer Res; 2003 Aug; 63(15):4561-7. PubMed ID: 12907632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infrequent CDKN2 mutation in human differentiated thyroid cancers.
    Tung WS; Shevlin DW; Bartsch D; Norton JA; Wells SA; Goodfellow PJ
    Mol Carcinog; 1996 Jan; 15(1):5-10. PubMed ID: 8561866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53 gene mutations in radiation-induced thyroid cancer.
    Fogelfeld L; Bauer TK; Schneider AB; Swartz JE; Zitman R
    J Clin Endocrinol Metab; 1996 Aug; 81(8):3039-44. PubMed ID: 8768871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.